Press Releases Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Delayed Japan Exchange Other stock markets 11:52:34 2024-04-29 pm EDT			5-day change	1st Jan Change
5,306 ^JPY	+5.91%		+13.98%	+37.27%

Apr. 29	AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement	MT
Apr. 29	AstraZeneca makes progress with Truqap and Enhertu cancer treatments	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial	Apr. 29	BU
Daiichi Sankyo : Announces Determination of Matters Relating to Acquisition and Cancellation of Own Shares(213.5KB	Apr. 25	PU
Daiichi Sankyo : FY2023 Reference Dat	Apr. 25	PU
Astrazeneca - Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-Positive solid tumours	Apr. 08	AQ
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB	Apr. 05	PU
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	Apr. 03	AQ
Daiichi Sankyo : REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB	Apr. 03	PU
Daiichi Sankyo : Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer(204.8KB	Apr. 02	PU
Daiichi Sankyo Announces Global Management Structure and CxOs	Apr. 01	AQ
Daiichi Sankyo : Datopotamab Deruxtecan New Drug Application Submitted in Japan for Patients with Previously Treated Advanced HR Positive, HER2 Negative Breast Cancer(190.8KB	Mar. 14	PU
Daiichi Sankyo : Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer (200.1KB	Mar. 04	PU
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer	Mar. 04	BU
Daiichi Sankyo : Expiration of Marketing Alliance Agreement for TENELIA® Tablets, TENELIA® OD Tablets and CANAGLU® Tablets(405KB	Mar. 04	PU
Mitsubishi Tanabe Pharma Corporation - Launch of Radicava for the Treatment of ALS in Brazil First successful launch by a partner in global expansion	Feb. 28	AQ
Daiichi Sankyo - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer	Feb. 20	AQ
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours	Feb. 08	AQ
Astrazeneca - ENHERTU granted Priority Review in the US for patients with metastatic HER2-positive solid tumors	Jan. 30	AQ
Daiichi Sankyo - ENHERTU Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors	Jan. 30	AQ
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors	Jan. 29	BU
U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen	Jan. 17	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Press Releases

Filters